D. Boral Capital Leads Propanc Biopharma's $4,000,000 Uplisting on Nasdaq

Propanc Biopharma has closed an underwritten public offering of 1,000,000 shares of common stock at $4.00 per share, raising $4,000,000. The shares began trading on the Nasdaq Capital Market on August 15, 2025. D. Boral Capital and Craft Capital Management acted as book running managers, with Brunson Chandler & Jones and Sichenzia Ross Ference Carmel serving as counsel. The offering was declared effective by the SEC on August 13, 2025.

Propanc Biopharma, Inc. (Nasdaq: PPCB) has successfully closed an underwritten public offering of 1,000,000 shares of its common stock at $4.00 per share, raising a total of $4,000,000. The shares began trading on the Nasdaq Capital Market on August 15, 2025, under the ticker symbol "PPCB" [1].

The offering was managed by D. Boral Capital LLC and Craft Capital Management LLC as book running managers, with legal counsel provided by Brunson Chandler & Jones, PLLC and Sichenzia Ross Ference Carmel LLP [1]. The registration statement on Form S-1 for these securities was declared effective by the U.S. Securities and Exchange Commission (SEC) on August 13, 2025 [1].

Propanc Biopharma is a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer. The company's lead asset, PRP, is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas, administered by intravenous injection. PRP acts as an "EMT (epithelial to mesenchymal transition) modulator" that reprograms cancer cells, making them no longer malignant and allowing them to die naturally [2].

With the successful completion of its IPO, Propanc Biopharma is now preparing to advance its lead asset, PRP, into a Phase 1B, First-In-Human (FIH) study. The study aims to identify the maximum tolerated dose (MTD) in 30-40 advanced cancer patients suffering from malignant solid tumors. The study is expected to commence in 2026 [2].

Propanc Biopharma has also expanded its management team and Board of Directors, appointing a Chief Financial Officer and two Non-Executive Directors. These appointments aim to strengthen the breadth of skills and capabilities of its personnel and the diversity of the leadership team [2].

References:
[1] https://www.nasdaq.com/press-release/d-boral-capital-acted-lead-bookrunner-propanc-biopharma-inc-nasdaq-ppcb-connection
[2] https://www.propanc.com/news-media/press-releases/detail/170/propanc-biopharma-provides-shareholder-update